Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications

Oral Diseases (2012) 18 , 692–699 Objectives: Current clinicopathological parameters cannot predict the risk of malignant transformation in oral leukoplakia sufficiently. Recent studies have shown that podoplanin is expressed in oral cancer and precancerous lesions. The aim of our study was to assess whether podoplanin expression in pretreatment biopsies could serve as a biomarker to predict the risk of malignant transformation in patients with oral leukoplakia. Materials and Methods: In this retrospective study, podoplanin expression was analysed in 60 patients with previously untreated oral leukoplakia by immunohistochemistry. We investigated the associations between podoplanin expression and various clinicopathological variables including oral cancer‐free survival (OCFS) and the SIN‐classification. Results: The chi‐square‐test revealed that high expression of podoplanin in pretreatment biopsies was associated with malignant transformation (P = 0.003) and increasing SIN‐classification (P = 0.009). In univariate analysis, podoplanin expression in oral leukoplakia had a significant impact on OCFS (P = 0.009). The 5‐year OCFS rate decreased from 100% for patients with no podoplanin expression to 41.7% for patients with the highest level of podoplanin expression. Conclusion: Although podoplanin expression and the SIN‐classification served as factors to predict malignant transformation in patients with oral leukoplakia in univariate analysis, no significant impact was found for both factors in multivariate analysis.     

Immunohistochemical examination for the distribution of podoplanin-expressing cells in developing mouse molar tooth germs

We recently reported the expression of podoplanin in the apical bud of adult mouse incisal tooth. This study was aimed to investigate the distribution of podoplanin-expressing cells in mouse tooth germs at several developing stages. At the bud stage podoplanin was expressed in oral mucous epithelia and in a tooth bud. At the cap stage podoplanin was expressed on inner and outer enamel epithelia but not in mesenchymal cells expressing the neural crest stem cell marker nestin. At the early bell stage nestin and podoplanin were expressed in cervical loop and odontoblasts. At the root formation stage both nestin and podoplanin were weakly expressed in odontoblasts generating radicular dentin. Podoplanin expression was also found in the Hertwig epithelial sheath. These results suggest that epithelial cells of developing tooth germ acquire the ability to express nestin, and that tooth germ epithelial cells maintain the ability to express podoplanin in oral mucous epithelia. The expression of podoplanin in odontoblasts was induced as tooth germ development advanced, but was suppressed with the completion of the primary dentin, suggesting that podoplanin may be involved in the cell growth of odontoblasts. Nestin may function as an intermediate filament that binds podoplanin in odontoblasts.     

PCDGF、Podoplanin在食管鳞癌中的表达及临床病理意义

目的 检测食管鳞癌组织中畸胎瘤源性生长因子(PC-cell-derived Growth Factor,PCDGF)及淋巴管的特异标记物podoplanin的表达情况及临床病理意义.方法 采用逆转录-聚合酶链反应(RT-PCR)检测经病理证实的40例食管鳞癌组织及加例切缘正常组织中的PCDGF mRNA的表达及用SP免疫组织化学法检测相同组织中podoplanin 的表达,计数淋巴管密度,分析二者与食管鳞癌进展及淋巴结转移的关系.结果 PCDGF在食管鳞癌中的表达率为95%(38/40),显著高于正常对照组40%(16/40),二者差异有统计学意义(P<0.01);podoplanin特异性染色淋巴管,未发现血管着色.淋巴管密度在食管鳞癌组为(7.21±3.2),明显高于正常对照组的(4.20±2.34)(P<0.05);且PCDGF及podoplanin的表达与食管鳞癌的分化程度及淋巴结转移有关.结论 PCDGF可能与食管鳞癌的演进及淋巴结转移有关,并有望成为一种新颖的食管鳞癌标记物.而podoplanin是特异淋巴管标记物,可作为判断食管癌淋巴结转移的指标.     

膀胱癌CD34及podoplanin表达情况与淋巴结转移及组织浸润的关系分析

目的：探讨膀胱癌组织中CD34及肾小球足突细胞膜黏蛋白（podoplanin）的表达情况,并分析其与淋巴结转移及组织浸润的关系。方法以45例膀胱癌患者作为观察组,10例正常者为对照组,对比两组膀胱组织中CD34及podoplanin表达情况;同时根据淋巴结是否发生转移,将观察组患者又分为无转移组及转移组,对比组间CD34及podoplanin表达情况;根据组织浸润情况,将观察组分为浸润未超过肌层的未浸润组及超过肌层的浸润组,对比两组间CD34及podoplanin表达情况。结果观察组患者CD34及podoplanin阳性表达率均高于对照组,差异比较具有统计学意义（P﹤0.05）;转移组CD34及podoplanin阳性表达率均高于无转移组,差异比较亦具有统计学意义（P﹤0.05）;浸润组CD34及podoplanin阳性表达率均高于无浸润组,差异比较具有统计学意义（P﹤0.05）。结论膀胱癌患者膀胱组织中CD34及podoplanin表达阳性率较正常者膀胱组织升高,且组织浸润超过肌层及发生淋巴结转移亦可使CD34及podoplanin阳性表达率升高。     

podoplanin在非小细胞肺癌组织中的表达及其与肿瘤淋巴转移的关系

目的研究podoplanin在非小细胞肺癌(NSCLC)组织中的表达及其与肺癌淋巴结转移的关系。方法应用免疫组化方法检测46例NSCLC组织标本和8例炎性假瘤组织标本中podoplanin、CD31和血管内皮生长因子受体-3(VEGFR-3)的表达,并记数淋巴管密度(LVD);分析podoplanin表达和肺癌淋巴转移的关系。结果Podoplanin显示的LVD与CD31显示的血管密度值(MVD)、VEGFR-3显示的微管密度值不相关(Spearman相关系数0.23,P=0.61;0.09,P=0.84);VEGFR-3阳性管数与CD31阳性管数相关(系数0.80,P=0.031,P<0.05)。在NSCLC组织LVD明显高于肺炎性假瘤组织LVD(P<0.01),与淋巴结转移阴性组比较,淋巴结转移阳性组LVD明显增高(P<0.05)。结论在NSCLC组织中,podoplanin是合适的淋巴管标记物,而VEGFR-3标记的微管多数是血管而不是淋巴管;podoplanin可作为判断NSCLC淋巴转移的指标,进而评价肺癌患者的预后。     

Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes

The spread of tumor cells to regional lymph nodes is an early event of gastric cancer metastasis. In our study, we assessed the expression of lymphangiogenic factors and lymphatic endothelial markers in gastric carcinoma tissues and compared expression levels with the status of lymph node metastasis. We also examined the correlation between lymphatic vessel density (LVD) in primary tumors and lymph node metastasis. Paired biopsy samples (tumor and corresponding normal mucosa) of gastric tissue were obtained from 39 patients with gastric carcinoma. The expression of VEGF-C, VEGF-D, VEGFR-3 and podoplanin mRNAs was assessed by real-time quantitative PCR. The expression of VEGF-C (but not of VEGF-D) was significantly greater in patients with lymph node metastasis than in those without metastasis. The expression of lymphatic endothelial markers VEGFR-3 and podoplanin was also significantly greater in the node-positive group. LVD, as assessed by immunohistochemistry for podoplanin, was correlated with lymph node metastasis. These results indicate that quantitative analysis of lymphangiogenic markers in gastric biopsy specimens may be useful in predicting metastasis of gastric cancer to regional lymph nodes.     

早期宫颈鳞癌癌周组织及盆腔淋巴结中podoplanin及高危型HPV的检测及意义

目的：检测早期宫颈鳞癌癌周组织及盆腔淋巴结中podoplanin及HPV16/18抗原的表达,寻求早期宫颈癌淋巴转移的标记物.方法：选取宫颈鳞癌57例,每例取1-3个淋巴结,共选取淋巴结103个,采用免疫组化方法检测podoplanin及HPV16/18的表达.结果：在有淋巴结转移的宫颈鳞癌癌周组织、无淋巴结转移的宫颈鳞癌癌周组织及正常宫颈组织中podoplanin的阳性率分别为76.2％（16/21）,41.7％ （15/36）,27.2％（6/22）.在淋巴转移患者的转移淋巴结,未转移淋巴结,及淋巴无转移患者的淋巴结中HPV16/18的阳性率分别为89.3％ （25/28）,60.0％ （18/30）,42.2％（19/45）,差异有统计学意义（P＜0.05）.二者的检测结果呈正相关.结论：联合检测盆腔淋巴结中HPV16/18和podoplanin抗原,有助于早期发现宫颈癌淋巴结微转移.Podoplanin可以作为检测宫颈癌淋巴转移的特异性标志.